TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02094677

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: filcon II 3
Description: Participants were randomized to wear filcon II 3 test lens.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: filcon II 3
Description: Participants were randomized to wear filcon II 3 test lens.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: Participants were randomized to wear etafilcon A control lens.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nelfilcon A
Description: Participants were randomized to wear nelfilcon A control lens.
Study: NCT00390468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tandutinib
Description: 500 mg twice daily every day with doses taken approximately 12 hours apart, 28 day cycle.
Study: NCT01871415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: 150 mcg orally daily
Study: NCT00545662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Drug Placebo Inactive twice a day given orally or enterally. The first dose is given within 24 hours of injury and treatment continues until 90 days or until the 90-day outcome assessment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citicoline
Description: 1000 mg twice a day orally or enterally. The first dose is within 24 hours of injury and treatment continues for 90-days or until the 90-day outcome assessment.
Study: NCT02923960

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard ONS
Description: One serving (237 ml) standard oral nutritional beverage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes specific ONS 1
Description: One serving (237 ml) diabetes oral nutritional beverage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes specific ONS 2
Description: One serving (296 ml) diabetes oral nutritional beverage
Study: NCT03873831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal-assisted intervention
Description: The therapy dog is present during the session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal-assisted intervention
Description: The therapy dog is present during the session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social skills group
Description: The group program is 10 weeks in duration, with 1-hour long sessions once per week. Children will be taught new social skills each week using an established teaching interaction procedure, in which the therapist first describes the target skill, provides a rational and context for the behavior, divides the skill into smaller steps, demonstrates the behavior, and has each learner role-play the skill while providing feedback in the form of praise and tokens and corrective instruction. The last week involves a probe free-play session, in which children are assessed in a more naturalistic environment without any corrective feedback from therapists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social skills group
Description: The group program is 10 weeks in duration, with 1-hour long sessions once per week. Children will be taught new social skills each week using an established teaching interaction procedure, in which the therapist first describes the target skill, provides a rational and context for the behavior, divides the skill into smaller steps, demonstrates the behavior, and has each learner role-play the skill while providing feedback in the form of praise and tokens and corrective instruction. The last week involves a probe free-play session, in which children are assessed in a more naturalistic environment without any corrective feedback from therapists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social skills group
Description: The group program is 10 weeks in duration, with 1-hour long sessions once per week. Children will be taught new social skills each week using an established teaching interaction procedure, in which the therapist first describes the target skill, provides a rational and context for the behavior, divides the skill into smaller steps, demonstrates the behavior, and has each learner role-play the skill while providing feedback in the form of praise and tokens and corrective instruction. The last week involves a probe free-play session, in which children are assessed in a more naturalistic environment without any corrective feedback from therapists.
Study: NCT02756013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80mg/m2 IV days 1,8, and 15 every 21 days x 6-9 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: area under the curve (AUC) 6 IV day 1 every 21 days x 6-9 cycles
Study: NCT04185428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Therapy
Description: still meditation, meditative movement, relaxation techniques, and massage therapy
Study: NCT03131765

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YS-0N-001
Description: Cancer vaccine
Study: NCT00727493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alendronate once weekly 70mg
Description: alendronate once weekly 70mg, calcium 1000mg and Vitamin D 800 IU daily for 12 months, dental implant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo once weekly; calcium 1000mg and Vitamin D 800 IU daily, dental implant
Study: NCT01871415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: pre-existing background regimen and dose
Study: NCT04227847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEA-CD70
Description: Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEA-CD70
Description: Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEA-CD70
Description: Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEA-CD70
Description: Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEA-CD70
Description: Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEA-CD70
Description: Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: 75mg/m\^2 injected under the skin (SC; subcutaneous) or given into the vein (IV; intravenously) on Days 1 through 7 of each treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: 75mg/m\^2 injected under the skin (SC; subcutaneous) or given into the vein (IV; intravenously) on Days 1 through 7 of each treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: 75mg/m\^2 injected under the skin (SC; subcutaneous) or given into the vein (IV; intravenously) on Days 1 through 7 of each treatment cycle.
Study: NCT01169428

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Weight Loss Maintenance (MBWLM)
Description: This mindfulness-meditation based intervention is designed to increase awareness of the factors that affect weight loss maintenance after successful weight loss. Mindfulness meditation is a technique for training awareness. The program will train subjects to increase awareness of the somatic, cognitive, affective, interpersonal and environmental factors that mediate eating and physical activity by incorporating empirically-supported and theoretically-synergized components, including: general mindfulness meditation skills, mindful and intuitive eating, appetite-satiety awareness, mindful movement and yoga, a mindful approach to exercise engagement, and training in enhancing emotion regulation and stress management skills. In addition, the MBWLM group will be supported by Maintenance Partners who are trained as Integrative Health Coaches.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral: Standard Behavioral Weight-Loss Maintenence
Description: Attention/Education/Support Control group, designed to control for educational content as well as nonspecific treatment factors \[e.g., natural history (time), amount of time and energy spent in the intervention, attention by group leaders, social support, as well as information \& education\]. Like the experimental group(MBWLM), this group meet once a week for 2 hours during the 12-week intervention, and then at 4 weeks, 8 weeks, and 12 weeks post the 12 week intervention. Participants also receive the same amount of telephonic support through Maintenance Partners as the experimental group, but their Maintenance Partners employed empathic listening only rather than myriad coaching techniques.
Study: NCT05527574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Participants are enrolled in 30-40 minutes of resistance exercise training using elastic bands for 30-40 minutes/session three times per week over six months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Participants are enrolled in 30-40 minutes of resistance exercise training using elastic bands for 30-40 minutes/session three times per week over six months
Study: NCT00829803

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SNAP monitor; Bispectral Index Monitor (BIS Monitor)
Description: Intended to monitor the state of the brain by data acquisition of EEG signals.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SNAP monitor; Bispectral Index Monitor (BIS Monitor)
Description: Intended to monitor the state of the brain by data acquisition of EEG signals.
Study: NCT00996775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief alcohol intervention
Description: this intervention consists of brief assessment and feedback

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: education about harmful effects of alcohol use and NIAAA recommended drinking limits
Study: NCT00110136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: St. John's Wort
Description: St. John's Wort 300mg tablet three times per day
Study: NCT00684346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18-FDG
Description: The administered intravenous dose of 18-FDG is 0.14mCi/kg up to a maximum of 10mCi before each PET imaging scan is performed.
Study: NCT02139631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Description: Assess the hemodynamic repercussions of the positive end expiratory pressure applied noninvasively
Study: NCT00848471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quark RMR
Description: Quark RMR calorimeter (Cosmed)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deltatrac II
Description: Deltatrac II (GE health Care Clinical Systems)
Study: NCT02250378

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: Undergo stereotactic radiosurgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo wedge resection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT02644135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Halo Oral Spray
Description: Three sprays per use, total = 9 sprays per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Halo Placebo
Description: Three sprays per use, total = 9 sprays per day
Study: NCT06478485

Intervention type: DIAGNOSTIC_TEST
Intervention: No Intervention: MCSM
Description: No Intervention: MCSM
Study: NCT01516346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Dinitrate
Description: Enrolled subjects will be randomized in a blinded fashion to 1 isosorbide dinitrate capsule TID + 1 placebo capsule TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs. Subjects receiving isosorbide dinitrate will be given 20mg PO q8am, 2pm, and 8pm and will be titrated up to 40mg PO q8am, 2pm, and 8pm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Dinitrate + Hydralazine
Description: Enrolled subjects will be randomized in a blinded fashion to 1 isosorbide dinitrate capsule TID + 1 hydralazine capsule TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs. Subjects receiving isosorbide dinitrate will be given 20mg PO q8am, 2pm, and 8pm and will be titrated up to 40mg PO q8am, 2pm, and 8pm. Subjects receiving hydralazine will be given 37.5mg PO q8am, 2pm, and 8pm and will be titrated up to 75mg PO q8am, 2pm, and 8pm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Enrolled subjects will be randomized in a blinded fashion to 2 placebo capsules TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs.
Study: NCT00952575

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyclonal anti-D immunoglobulin
Description: single injection of 300 µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: monoclonal anti-D immunoglobulin
Description: Comparison of different dosages of LFB-R593
Study: NCT03673215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human thrombopoietin
Description: Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human thrombopoietin
Description: Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class B.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human thrombopoietin
Description: Recombinant human thrombopoietin will be administered single dose 150 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human thrombopoietin
Description: Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human thrombopoietin
Description: Recombinant human thrombopoietin will be administered single dose 450 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
Study: NCT02628743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olesoxime
Description: Participants will receive homogeneous suspension of olesoxime.
Study: NCT01796613

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Ring - intermittent regimen
Description: NuvaRing® used intermittently. Nuvaring is a contraceptive vaginal ring, manufactured by N.V. Organon (a subsidiary of Merck \& Co., Inc.,), Oss, the Netherlands. It contains 11.7 mg etonogestrel and 2.7 mg ethinylestradiol. It releases etonogestrel and ethinylestradiol at an average amount of 0.120 mg and 0.015 mg, respectively per 24 hours, over a period of 3 weeks. It is approved since 2001 by most countries within the European Union, and in the United Stated by the FDA.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Ring - continuous regimen
Description: NuvaRing® used continuously. Nuvaring is a contraceptive vaginal ring, manufactured by N.V. Organon (a subsidiary of Merck \& Co., Inc.,), Oss, the Netherlands. It contains 11.7 mg etonogestrel and 2.7 mg ethinylestradiol. It releases etonogestrel and ethinylestradiol at an average amount of 0.120 mg and 0.015 mg, respectively per 24 hours, over a period of 3 weeks. It is approved since 2001 by most countries within the European Union, and in the United Stated by the FDA.
Study: NCT03673215

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
Study: NCT01871415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: pre-existing background regimen and dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: matching aleglitazar placebo orally daily
Study: NCT04463238

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Guided cartilage regeneration membrane
Description: On the basis of microfracture, the blood clot released from the defect area is covered with a guide cartilage regeneration membrane to provide an attached scaffold for the cells in the blood clot.
Study: NCT04578639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: A prospective randomized double blinded multicenter non-inferiority study designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients (male or female) with active relapsing-remitting multiple sclerosis aged 18-60 years. Active substance is biosimilar rituximab iv infusion and comparator is ocrelizumab (Ocrevus ®) iv infusion. Both treatments are given as infusion at month 0, month 6, month 12, month 18 and month 24. Randomization rituximab: ocrelizumab is 3:2. The primary end-point is proportion of patients with no new or enlarging T2-weighted brain MRI lesions between re-baselining at month 6 and month 24.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ocrelizumab
Description: A prospective randomized double blinded multicenter non-inferiority study designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients (male or female) with active relapsing-remitting multiple sclerosis aged 18-60 years. Active substance is biosimilar rituximab iv infusion and comparator is ocrelizumab (Ocrevus ®) iv infusion. Both treatments are given as infusion at month 0, month 6, month 12, month 18 and month 24. Randomization rituximab: ocrelizumab is 3:2. The primary end-point is proportion of patients with no new or enlarging T2-weighted brain MRI lesions between re-baselining at month 6 and month 24.
Study: NCT03692130

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness, Acceptance and Commitment-Therapy
Description: Psychotherapeutic intervention to treat depressive patients with special exercises and education to be mindful, to accept situations and behaviors and to commit with the situation or the possibility to change.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Jacobson
Description: Relaxation treatment in technique of Jacobson
Study: NCT01957722

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: Surgical procedure which creates a marrow clot in the prepare cartilage defect.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NOVOCART 3D
Description: combination product- biologic (autologous chondrocytes) /device (scaffold) implant
Study: NCT00941785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA-PQ
Description: Three monthly administrations of Duocotexcin (DHA-PQ):~dihydroartemisinin 2.1mg/kg and piperaquine phosphate 16.8 mg/kg once daily for three days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP-AQ
Description: Three monthly administrations of sulfadoxine-pyrimethamine plus amodiaquine:~One dose of Sulfadoxine 25mg/kg and pyrimethamine 1.25mg/kg Three daily doses of amodiaquine phosphate 10mg/kg
Study: NCT01915082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Zithromax® oral suspension 200 mg/ 5 mL (Pfizer, UK):~Zithromax® 1000 mg syrup per os once at recipient intake for lung transplantation (day 0); followed by Zithromax® 250 mg syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ora-Plus
Description: Ora-Plus® oral suspension (Paddock Laboratories, 3940 Quebec Avenue N, Minneapolis, MN 55427, USA; NDC-number: 0574-0303-16):~Ora-Plus® 25mL syrup per os once at recipient intake for lung transplantation (day 0); followed by Ora-Plus® 6.25 mL syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31).
Study: NCT02716428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-6450
Study: NCT04463238

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microfracture
Description: Operate in accordance with the clinical microfracture surgery method.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Microfracture
Description: Operate in accordance with the clinical microfracture surgery method.
Study: NCT03690674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Enhancement for ADHD Program
Description: The LEAP intervention consists of 3 components: 1) an enhanced 8-week, group-based BMT curriculum, 2) parent and child use of the Garmin daily activity tracker accompanied by personalized goal setting, and 3) parent participation in a private Facebook group to encourage PA goal achievement and promote social support and positive parenting.